Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer

Дата публикации: 25-06-2026 00:00:00

This secondary analysis of a randomized clinical trial evaluates 5-year outcomes and characterizes circulating tumor DNA dynamics in patients with ERBB2-positive breast cancer treated with 12 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	0	7	25-06-2026
2	Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors	0	7	25-06-2026
3	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
4	Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma	5	7	30-06-2026
5	Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy	0	7	18-06-2026
6	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
7	Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer	7	8	01-07-2026
8	Survival in the SONIA Trial	0	7	18-06-2026
9	EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan	0	5	26-06-2026
10	Survival in the SONIA Trial	0	8	18-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.